GSK Exceeds Expectations In Q2, But Still Awaiting Shingrix Bounce Back

Pandemic Will Continue To Affect Shingles Vaccine

 
• By Andrew McConaghie
  
GSK
Shingrix brought in £1.98bn ($2.76bn) last year, but will not show much growth in 2021.

More from Earnings

More from Business